These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 24578754)

  • 1. Efficacy of combination therapy with sitagliptin and low-dose glimepiride in Japanese patients with type 2 diabetes.
    Ishii H; Ohkubo Y; Takei M; Nishio S; Yamazaki M; Kumagai M; Sato Y; Suzuki S; Aoki Y; Miyamoto T; Kakizawa T; Sakuma T; Komatsu M
    J Clin Med Res; 2014 Apr; 6(2):127-32. PubMed ID: 24578754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S; Saxena GN; Keshwani P; Gupta R
    J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus.
    Hirao K; Maeda H; Shirabe S; Yamamoto R; Hirao T; Hirao S; Yamauchi M; Arai K
    Jpn Clin Med; 2012; 3():1-7. PubMed ID: 23946679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination.
    Shimoda S; Iwashita S; Sekigami T; Furukawa N; Matsuo Y; Ichimori S; Goto R; Maeda T; Watanabe E; Kondo T; Matsumura T; Motoshima H; Nishida K; Araki E
    J Diabetes Investig; 2014 May; 5(3):320-6. PubMed ID: 24843781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Sitagliptin on Pancreatic Beta-Cells in Type 2 Diabetes With Sulfonylurea Treatment: A Prospective Randomized Study.
    Sato A; Takei M; Hiramatsu K; Takeda T; Miyamoto T; Yamazaki M; Sato Y; Komatsu M
    J Clin Med Res; 2019 Jan; 11(1):15-20. PubMed ID: 30627273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial.
    Kondo Y; Harada N; Hamasaki A; Kaneko S; Yasuda K; Ogawa E; Harashima S; Yoneda H; Fujita Y; Kitano N; Nakamura Y; Matsuo F; Shinji M; Hinotsu S; Nakayama T; Inagaki N;
    Diabetol Metab Syndr; 2016; 8():15. PubMed ID: 26925169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a sitagliptin safety alert on prescription behaviour for oral antihyperglycaemic drugs: a propensity score-matched cohort study of prescription receipt data in Japan.
    Sato D; Sato Y; Masuda S; Kimura H
    Drug Saf; 2013 Aug; 36(8):605-15. PubMed ID: 23700263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Handelsman Y; Lauring B; Gantz I; Iredale C; O'Neill EA; Wei Z; Suryawanshi S; Kaufman KD; Engel SS; Lai E
    Curr Med Res Opin; 2017 Oct; 33(10):1861-1868. PubMed ID: 28548024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal candidates for the switch from glimepiride to sitagliptin to reduce hypoglycemia in patients with type 2 diabetes mellitus.
    Kim HM; Lim JS; Lee BW; Kang ES; Lee HC; Cha BS
    Endocrinol Metab (Seoul); 2015 Mar; 30(1):84-91. PubMed ID: 25325279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).
    Terawaki Y; Iwaya C; Nomiyama T; Shimono D; Horikawa T; Fujimura-Tanaka Y; Shigeoka T; Hamanoue N; Motonaga R; Tanabe M; Yanase T; Kawanami D;
    Diabetol Int; 2020 Jul; 11(3):274-282. PubMed ID: 32802709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of sitagliptin when added to ongoing therapy in korean subjects with type 2 diabetes mellitus.
    Chung HS; Lee MK
    Diabetes Metab J; 2011 Aug; 35(4):411-7. PubMed ID: 21977462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sitagliptin 100 mg vs glimepiride 1-3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM).
    Kesavadev J; Pillai PBS; Shankar A; Krishnan G; Jothydev S
    Endocr Connect; 2017 Nov; 6(8):748-757. PubMed ID: 28982699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Muscle Mass and the Muscle/Fat Ratio in Patients With Type 2 Diabetes.
    Ishii S; Nagai Y; Kato H; Fukuda H; Tanaka Y
    J Clin Med Res; 2020 Feb; 12(2):122-126. PubMed ID: 32095182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34⁺CXCR4⁺ cells in patients with type 2 diabetes.
    Aso Y; Jojima T; Iijima T; Suzuki K; Terasawa T; Fukushima M; Momobayashi A; Hara K; Takebayashi K; Kasai K; Inukai T
    Endocrine; 2015 Dec; 50(3):659-64. PubMed ID: 26209038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.
    Chwieduk CM
    Drugs; 2011 Feb; 71(3):349-61. PubMed ID: 21319871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the sitagliptin alert on prescription of oral antihyperglycemic drugs in Japan.
    Sato D; Sato Y; Masuda S; Kimura H
    Int J Clin Pharm; 2012 Dec; 34(6):917-24. PubMed ID: 22941471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.